Effects of Older Donor Age and Cold Ischemic Time on Long-Term Outcomes of Heart Transplantation

Using older donor hearts in cardiac transplantation may lead to inferior outcomes: older donors have more comorbidities that reduce graft quality, including coronary artery disease, hypertension, diabetes mellitus, and dyslipidemia. Shorter cold ischemic times might overcome the detrimental effect of older donor age. We examined the relationship between donor allograft age and cold ischemic time on the long-term outcomes of heart transplant recipients.

From 1994 through 2010, surgeons at our hospital performed 745 heart transplantations. We retrospectively classified these cases by donor ages of <50 years (younger) and ≥50 years (older), then by cold ischemic times of <120 min (short), 120 to 240 min (intermediate), and >240 min (long). Endpoints included recipient and graft survival, and freedom from cardiac allograft vasculopathy, nonfatal major adverse cardiac events, and rejection.

For intermediate ischemic times, the 5-year recipient survival rate was lower when donors were older (70% vs 82.6%; \(P=0.02\)). This was also true for long ischemic times (69.8% vs 87.6%; \(P=0.09\)). For short ischemic times, we found no difference in 5-year recipient or graft survival rates (80% older vs 85.6% younger; \(P=0.79\)), in freedom from nonfatal major adverse cardiac events (83.3% vs 91.5%; \(P=0.46\)), or in freedom from cardiac allograft vasculopathy (50% vs 70.6%; \(P=0.66\)). Rejection rates were mostly similar.

Long-term graft survival in heart transplantation patients with older donor allografts may improve when cold ischemic times are shorter. (Tex Heart Inst J 2018;45(1):17-22)

In the United States, the prevalence of heart failure in adults is projected to rise from 5.7 million currently to more than 8 million by 2030.\(^1\) Survival rates after a diagnosis of heart failure have improved; however, the one-year mortality rate (~30%)\(^2\)\(^-\)\(^4\) and the median survival duration (5 yr)\(^3\) have not. In contrast, after heart transplantation, the one-year survival rate is 82% and the median survival duration is 11 years.\(^5\) Heart transplantation improves quality of life\(^6\) and is the sole definitive treatment for advanced heart failure. However, the finite availability and varying quality of donor organs have limited the number of transplantations performed and have adversely affected after-transplantation outcomes. Criteria that influence donor–recipient matching include physical distance and the concomitant cold ischemic time (CIT), as well as donor age, antibody profiles, body size, ABO blood type, comorbidities, and heart function.\(^7\)

In the U.S., only 34% of potential donor hearts were accepted from 1995 through 2010, and despite national efforts to increase organ usage, donor-heart acceptance rates steadily decreased from 1995 through 2008 and increased only at the end of the analysis period (2008–2010).\(^4\) The decline in organ usage might indicate a greater avoidance of high-risk donors. Although most high-risk factors are robustly associated with nonuse of donor organs, these factors are not reliable predictors of adverse events after transplantation.\(^2\) Expanding the donor pool potentially involves re-evaluating the use of organs that might previously have been avoided, such as those from older donors.

The use of cardiac allografts from older donors increased over time through 2010 and then remained stable.\(^1\) In the 2015 report from the International Society for Heart and Lung Transplantation (ISHLT), the median heart-donor age was 35 years (5th to 95th percentile, 17–57 yr).\(^1\) Earlier ISHLT registry data revealed that older donor age was a significant predictor of death at one year and 5 years after heart transplantation, but not at 15 years; and the correlation between older donor age and higher recipient mortality rates remained significant after multivariate analysis.\(^10\)

Older donor
Age has also been associated with a higher incidence of cardiac allograft vasculopathy (CAV).\textsuperscript{1,11,12} Study results have indicated a possibly important interaction between CIT and donor age: CITs <3.5 hr were associated with superior survival rates, and hearts from younger donors better tolerated longer CITs.\textsuperscript{13} Approaches to improve outcomes in recipients of older allografts are poorly defined and perhaps could include more specific criteria in regard to projected CITs. We therefore investigated the effect of CIT on transplantation outcomes when cardiac donors are older.

Patients and Methods

This study was reviewed and approved by the Cedars-Sinai Institutional Review Board.

From 1994 through 2010, 745 heart transplantations were performed in our institution. We divided this group into recipients of hearts from donors who were <50 years old and ≥50 years old, and we further categorized CIT as short (<120 min), intermediate (120–240 min), and long (>240 min) (Fig. 1). We chose the age threshold because survival rates are reportedly inferior when donor allografts are >50 years old.\textsuperscript{14} Short CITs were associated with local donors (short travel times) and fewer repeat transplantations among patients in this subgroup. Donor selection criteria between groups varied only in terms of our institutional practice of requesting coronary angiography routinely in older donors and selectively otherwise. Younger donors underwent angiography only if additional risk factors were present, such as chronic diabetes mellitus, tobacco smoking, or family history of heart disease. In addition, we have a lower threshold for intraoperative evaluation of cardiac filling pressures when donors are older.

Endpoints. We prospectively gathered data on relevant clinical endpoints and entered them into our institution’s heart transplantation research database. We retrospectively evaluated the following endpoints at 5 years after transplantation: actuarial graft survival; freedom from CAV (defined as coronary artery stenosis ≥30%); and freedom from nonfatal major adverse cardiac events (NF-MACE), defined as myocardial infarction, congestive heart failure, percutaneous coronary intervention, pacemaker or defibrillator implantation, or stroke. In addition, we evaluated one-year freedoms from treated rejection: cellular, antibody-mediated, biopsy-negative, and combined.

Statistical Analysis

We used unpaired Student \( t \) tests to compare continuous variables between groups (reported as mean ± SD). We used the Fisher exact test to compare categorical variables between groups (reported as percentage). Analyses of survival and freedom from events were performed by using the Kaplan-Meier method; comparison between groups was with log-rank tests. Two-tailed \( P \) values <0.05 were considered significant. All statistical analyses were performed with use of SPSS version 22 (SPSS Inc., an IBM company).

Results

Table I shows the recipients’ demographic data. The mean donor age in the short-CIT group was 29.6 ± 10.9 years for those <50 versus 55.5 ± 7.4 for those ≥50 years old; for intermediate CITs, it was 29 ± 10.3 versus 53.8 ± 3.2; and for long CITs, it was 30.1 ± 10.1 versus 54.9 ± 2.8 years (all \( P <0.001 \)). The frequency of sensitization (pretransplantation panel-reactive antibody, >10%) was higher in recipients of older hearts in the long-CIT group. In the long-CIT groups only, the prevalence of Status 1 listings was higher in the younger donor group. Other demographic variables were similar.

Our most important finding is that older donor age was not detrimental to recipient survival outcomes when CITs were short (Fig. 2). No recipient in the short-CIT group needed mechanical circulatory support after transplantation. For intermediate CITs, the 5-year recipient survival rate was significantly lower when donors were older (70% vs 82.6%; \( P =0.02 \)) (Table II). Similar results were seen for long CITs: 69.8% for older donors versus 87.6% for younger (\( P =0.09 \)). In contrast, for short CITs, we found no significant difference in 5-year survival rates in terms of age (80% vs 85.6%; \( P =0.789 \)).
In older-allograft recipients in the long-CIT subgroups, we identified no differences in graft survival (69.8% older vs 86% younger; \(P = 0.151\)), freedom from CAV (69.4% vs 80.7%; \(P = 0.62\)), or freedom from NF-MACE (76.2% vs 88.9; \(P = 0.134\)). For intermediate CITs, these 3 outcomes were significantly poorer in recipients of older allografts (\(P = 0.008\), \(P = 0.001\), and \(P = 0.034\)). For short CITs, we found similarity in 5-year graft survival rates (80% vs 85.6%; \(P = 0.789\)), freedom from CAV (50% vs 70.6%; \(P = 0.663\)), and freedom from NF-MACE (83.3% vs 91.5%; \(P = 0.464\)).

Older donor allografts were associated with less freedom from treated cellular rejection than were younger ones for short CITs (66.7% vs 95.8%; \(P = 0.004\), but not for intermediate or long CITs. We identified no significant differences in other rejection rates.

The causes of death in recipients were similar across the groups (Table III). Chief among these were non-cytomegalovirus infection, graft failure, rejection, and CAV.

**Discussion**

Older donor age and long CIT have consistently correlated with higher one-year mortality rates after heart transplantation.\(^{10,15-17}\) Less established is whether mini-
### TABLE II. Outcomes by Cold Ischemic Time and Donor Age

| Cold Ischemic Time | <120 min | 120–240 min | >240 min |
|--------------------|----------|-------------|----------|
|                    | <50 yr (n=49) | ≥50 yr (n=6) | <50 yr (n=490) | ≥50 yr (n=60) | <50 yr (n=126) | ≥50 yr (n=14) | P Value |
| 5-Year actuarial   |          |             |          |             |          |             |       |
| Recipient survival | 85.6     | 80          | 82.6     | 70          | 87.6     | 69.8        | 0.09   |
| Graft survival     | 85.5     | 66.7        | 88.3     | 89.4        | 86.1     | 76.2        | 0.353  |
| Freedom from CAV   | 70.6     | 50          | 76       | 51.1        | 94.2     | 83.9        | 0.158  |
| Freedom from NF-MACE | 91.5    | 83.3        | 80.8     | 68.5        | 88.9     | 76.2        | 0.134  |
| 1-Year freedom     |          |             |          |             |          |             |       |
| Any treated rejection | 85.5  | 66.7        | 88.3     | 89.4        | 86.1     | 76.2        | 0.353  |
| Treated cellular rejection | 95.8 | 66.7       | 94.8     | 94.7        | 94.2     | 83.9        | 0.158  |
| Treated antibody-mediated rejection | 91.7  | 100        | 94.2     | 94.7        | 92.7     | 92.3        | 0.944  |
| Biopsy-negative rejection | 97.9 | 100        | 98.3     | 98.2        | 97.5     | 100         | 0.579  |

CAV = cardiac allograft vasculopathy defined by ≥30% coronary artery stenosis; NF-MACE = nonfatal major adverse cardiac events (myocardial infarction, congestive heart failure, percutaneous coronary intervention, pacemaker or defibrillation implantation, or stroke)

Data were calculated with use of the Kaplan-Meier method and are presented as percentage.  P <0.05 was considered statistically significant.

### TABLE III. Causes of Death in Allograft Recipients by Cold Ischemic Time and Donor Age

| Cause of Death | Cold Ischemic Time | Overall |
|----------------|--------------------|---------|
|                | <120 min | 120–240 min | >240 min | Overall |
|                | <50 yr (n=49) | ≥50 yr (n=6) | <50 yr (n=490) | ≥50 yr (n=60) | <50 yr (n=126) | ≥50 yr (n=14) |       |
| CAV            | 0         | 0           | 13 (2.7) | 1 (1.7) | 0         | 1 (7.1) | 15 (2) |
| Rejection      | 0         | 0           | 11 (2.2) | 4 (6.7) | 4 (3.2)  | 0       | 19 (2.6) |
| Lymphoma       | 0         | 0           | 0        | 0        | 1 (0.8)  | 0       | 1 (0.1) |
| Other malignancy | 0       | 0           | 8 (1.6)  | 0        | 0        | 0       | 8 (1.1) |
| Non-CMV infection | 1 (2)  | 0           | 15 (3.1) | 5 (8.3) | 5 (4)    | 1 (7.1) | 27 (3.6) |
| Graft failure  | 5 (10)    | 1 (16.7)    | 12 (2.4) | 2 (3.3) | 2 (1.6)  | 2 (14.3) | 24 (3.2) |
| Technical failure | 0       | 0           | 1 (0.2)  | 0        | 2 (1.6)  | 0       | 3 (0.4) |
| Other          | 0         | 0           | 4 (0.8)  | 1 (1.7) | 1 (0.8)  | 0       | 6 (0.8) |
| Renal failure  | 0         | 0           | 2 (0.4)  | 0        | 0        | 0       | 2 (0.3) |
| Pulmonary      | 1 (2)     | 0           | 4 (0.8)  | 3 (5)    | 0        | 0       | 8 (1.1) |
| Cerebrovascular | 0       | 0           | 5 (1)    | 1 (1.7) | 0        | 0       | 6 (0.8) |
| Unknown        | 0         | 0           | 8 (1.6)  | 0        | 0        | 0       | 8 (1.1) |
| TOTAL          | 7 (14.3)  | 1 (1.7)     | 83 (16.9)| 17 (28.3)| 15 (11.9)| 4 (28.6)| 127 (100) |

CAV = cardiac allograft vasculopathy (≥30% coronary artery stenosis); CMV = cytomegalovirus

No patient died of multiple-organ failure. Data are presented as number and percentage.
mizing CIT reduces the negative influence of older age. In the current study, 5-year survival rates at short CITs were similar regardless of allograft age; however, at CITs beyond 120 min, the negative impact of older age was apparent.

Damage to harvested organs can occur after periods of relative hypoxia and limited nutrient availability, followed by additional injury and inflammation associated with reperfusion. Because of age-associated changes, an older donor heart may be particularly susceptible to injury and have less regenerative capacity.14 Left ventricular hypertrophy may also have negative effects. Therefore, optimal organ preservation and short CIT would seem to be particularly important in older cardiac allografts. An important consideration for future research is whether older donor hearts can benefit from alternative protective approaches, such as improved perfusion during transportation.

Investigators have reported an association between donor age and CIT, with a negative impact of CIT on recipients’ survival outcome that was significant only when donors were older than 50 years.15 Authors who analyzed the United Network for Organ Sharing database for recipient survival rates after heart transplantation reported a significant effect of CIT that depended on donor age, with greater tolerance for prolonged CITs when grafts came from younger donors.13 The results of the current study confirm an important relationship between donor age, CIT, and outcomes, and implies that older hearts are more viable at CIT <120 min.

We are typically cautious about accepting older hearts with long CITs. However, if a recipient’s status is deteriorating, we might accept greater risk if all other donor variables are favorable, such as short harvest time, the absence of coronary artery disease and left ventricular hypertrophy, and death from causes other than cerebrovascular accident.

Limitations. Our study is subject to the limitations inherent to a retrospective analysis, including the potential for selection bias and other confounding variables. In addition, this study was observational and uncontrolled; however, substantial logistic and ethical challenges would complicate a prospective, randomized study of CITs for younger and older donors. Sample sizes were small, particularly in the short- and long-CIT groups, so our findings need larger studies for confirmation.

Conclusion

We found that recipients of older hearts at short CITs (<120 min) had long-term outcomes comparable to those of recipients of younger hearts at CITs <120 min. Recipients of older hearts at a CIT of either 120 to 240 min or >240 min had worse 5-year outcomes than did recipients of younger hearts in each time group. Long-term graft survival in heart transplantation patients with older donor allografts may improve when CITs are shorter.

Acknowledgment

The authors thank Ms Sadia Dimbil for assistance in collecting the data.

References

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015;131(4):e29-322.
2. Krumholz HM, Normand SL, Wang Y. Trends in hospitalizations and outcomes for acute cardiovascular disease and stroke, 1999-2011. Circulation 2014;130(12):966-75.
3. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292(3):344-50.
4. Chang PP, Chambless LE, Shahar E, Bertoni AG, Russell SD, Ni H, et al. Incidence and survival of hospitalized acute uncomplicated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 2014;113(3):504-10.
5. Lund LH, Edwards LB, Kucheryavaya AY, Benzen D, Dipchand AI, Goldfarb S, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report—2015; focus theme: early graft failure. J Heart Lung Transplant 2015;34(10):1244-54.
6. Grady KL, Naftel DC, Kobashigawa J, Chait J, Young JB, Pelegrin D, et al. Patterns and predictors of quality of life at 5 to 10 years after heart transplantation. J Heart Lung Transplant 2007;26(5):535-43.
7. Kilic A, Emanu S, Sai-Sudhakar CB, Higgins RS, Whitson BA. Donor selection in heart transplantation. J Thorac Dis 2014;6(8):1097-104.
8. Khush KK, Zaroff JG, Nguyen J, Menza R, Goldstein BA. National decline in donor utilization with regional variability: 1995-2010. Am J Transplant 2015;15(3):642-9.
9. Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA. Donor predictors of allograft use and recipient outcomes after heart transplantation. Circ Heart Fail 2013;6(2):300-9.
10. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report—2013; focus theme: age. J Heart Lung Transplant 2013;32(10):951-64.
11. Nagji AS, Hraniec T, Swenson BR, Kern JA, Bergin JD, Jones DR, et al. Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: implications for donor allocation. Ann Thorac Surg 2010;90(1):168-75.
12. Tehrani YS, Yu Z, Luu M, Liou F, Rafiei M, Hamilton M, Kobashigawa JA. The policy of placing older donors into older recipients: is it worth the risk? Clin Transplant 2014;28(7):802-7.
13. Russo MJ, Chen JM, Sorabella RA, Martens TP, Garrido M, Davies RR, et al. The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 2007;133(2):554-9.
14. Del Rizzo DF, Menkin AH, Pflugfelder PW, Novick RJ, McKenzie FN, Boyd WD, Kostuk WJ. The role of donor
15. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report–2014; focus theme: retransplantation. J Heart Lung Transplant 2014;33(10):996-1008.

16. Stehlik J, Feldman DS, Brown RN, VanBakel AB, Russel SD, Ewald GA, et al. Interactions among donor characteristics influence post-transplant survival: a multi-institutional analysis. J Heart Lung Transplant 2010;29(3):291-8.

17. Topkara VK, Cheema FH, Kesavaramanujam S, Mercando ML, Forster CS, Argenziano M, et al. Effect of donor age on long-term survival following cardiac transplantation. J Card Surg 2006;21(2):125-9.

18. Slegtenhorst BR, Dor FJ, Elkhal A, Rodriguez H, Yang X, Edringer K, et al. Mechanisms and consequences of injury and repair in older organ transplants. Transplantation 2014;97(11):1091-9.